Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Neoplasms × Nivolumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 108 Carcinoma, Non-Small-Cell Lung 88 Carcinoma, Renal Cell 63 Neoplasm Metastasis 44 Squamous Cell Carcinoma of Head and Neck 39 Colorectal Neoplasms 38 Neoplasms 32 Lung Neoplasms 30 Stomach Neoplasms 28 Carcinoma, Hepatocellular 28 Ovarian Neoplasms 19 Urinary Bladder Neoplasms 18 Hodgkin Disease 18 Brain Neoplasms 18 Pancreatic Neoplasms 17 Carcinoma, Transitional Cell 16 Skin Neoplasms 15 Head and Neck Neoplasms 15 Glioblastoma 15 Triple Negative Breast Neoplasms 14 Prostatic Neoplasms 14 Colonic Neoplasms 14 Sarcoma 13 Kidney Neoplasms 12 Carcinoma, Merkel Cell 12 Uveal Melanoma 11 Recurrence 11 Breast Neoplasms 11 Adenocarcinoma Of Esophagus 11 Uterine Cervical Neoplasms 10

Interventions

Gemcitabine 6 Cisplatin 6 pembrolizumab 4 Radiotherapy, Intensity-Modulated 3 Capecitabine 2 Bevacizumab 2 toripalimab 1 tocilizumab 1 tislelizumab 1 spartalizumab 1 penpulimab 1 atezolizumab 1 Vitamin D 1 Tablets 1 Surveys and Questionnaires 1 Phantoms, Imaging 1 Oral Hygiene 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Injections 1 Immunotherapy 1 Immunohistochemistry 1 Immunoglobulin G 1 Fluorouracil 1 Docetaxel 1 Disulfides 1 Dexamethasone 1 Chemoradiotherapy 1 Cetuximab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04875611 2025-04-24

NIVONASO-21

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡